MoFo Advises Celadon Partners in $47.6 Million PIPE Financing in Senti Biosciences

Morrison Foerster advised Celadon Partners in its private investment in public equity (“PIPE”) financing in NASDAQ-listed Senti Biosciences, Inc.(NASDAQ:SNTI) (“Senti Bio”).

Founded in 2016, Senti Bio is a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform.

The $47.6 million PIPE financing was led by Celadon Partners, with participation from New Enterprise Associates (NEA), Leaps by Bayer, Nantahala Capital, The Red Hook Fund LP, and other institutional and accredited investors. Senti Bio intends to use the funds raised in advancing the development of its SENTI-202 program, enhancing manufacturing capabilities, and supporting ongoing research and development and for general corporate purposes.

The MoFo deal team advising Celadon Partners on the transaction was led by Hong Kong partner and global co-chair of the firm’s Private Equity Group Marcia Ellis, San Francisco M&A/Public Company partner Michael O’Bryan and New York Capital Markets partner John Owen. Key members of the team included Hong Kong PE/M&A associate Yilong Luo and Austin Capital Markets associate Eric Harper. The successful completion of this transaction underscores MoFo’s deep private equity expertise in the biotechnology sector.

For more information, please refer to Senti Bio’s press releases issued on December 2, 2024 and January 6, 2025.

Apart from this transaction, MoFo also previously advised Celadon Partners and GeneFab in the launch of CRDMO business and acquisition of CMC capabilities from Senti Bio. Learn more about MoFo’s private equity practice.